Core B: Pharmaceutical Production

$443,320P01FY2017CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications & trials

Paper 39606437 Paper 39441907 Paper 39210036 Paper 39169114 Paper 38914227 Paper 38640253 Paper 38388647 Paper 38380817 Paper 37939122 Paper 37844282 Paper 37477588 Paper 36672303 Paper 36577856 Paper 36289434 Paper 36240285 Paper 36179985 Paper 36134457 Paper 36030308 Paper 35924583 Paper 35440690 Paper 35350938 Paper 34995355 Paper 34649272 Paper 34390541 Paper 33830025 Paper 33225057 Paper 33065723 Paper 33054108 Paper 32825022 Paper 32693211 Paper 32693210 Paper 32603426 Paper 32499241 Paper 31974434 Paper 31958813 Paper 31796913 Paper 31678540 Paper 31637757 Paper 31582553 Paper 31558788 Paper 31551243 Paper 31481800 Paper 31255743 Paper 31248843 Paper 31084888 Paper 30992266 Paper 30804488 Paper 30711779 Paper 30668198 Paper 30630975 Paper 30500442 Paper 30454872 Paper 30429336 Paper 30335787 Paper 30262560 Paper 30010833 Paper 29753836 Paper 29656138 Paper 29654289 Paper 29545343 Paper 29296873 Paper 29032276 Paper 28970176 Paper 28958896 Paper 28677267 Paper 28596425 Paper 28478120 Paper 28209721 Paper 28140754 Paper 28013013 Paper 27861292 Paper 27570067 Paper 27454657 Paper 27430015 Paper 27311969 Paper 27214071 Paper 27132278 Paper 27013013 Paper 27002921 Paper 26947200 Paper 26764356 Paper 26437070 Paper 26338894 Paper 26288023 Paper 26265463 Paper 26207349 Paper 26181003 Paper 26133610 Paper 26052908 Paper 25988188 Paper 25983023 Paper 25965411 Paper 25945807 Paper 25919226 Paper 25862589 Paper 25795719 Paper 25682602 Paper 25644959 Paper 25599167 Paper 25445025

Abstract

ABSTRACT - CORE B Core B is responsible for the production of clinical grade anti-human CD45 BC8 antibody (Projects 2 and 3). The antibody will be conjugated with a reagent (B10-NCS) for radiolabeling with astatine-211. All antibodies and clinical grade reagents will be produced, purified and vialed in the Biologics Production Facility of the Fred Hutchinson Cancer Research Center. Pre-clinical and clinical radiolabeling reactions will be conducted in appropriate radiochemistry laboratories at the University of Washington. Clinical grade BC8-B10 will be produced under current good manufacturing practice (cGMP) conditions and a Drug Master File will be developed and submitted to the Food and Drug Administration. In addition, Core B will be responsible for the establishment of an IND to support conduct of Phase I human clinical trials. Core B will also be responsible for radiolabeling anti-canine ICOS with 123I and 211At which are required for biodistribution and therapy studies respectively for Project 1. The anti-ICOS antibody itself will be produced using resources supplied to Project 1.

View original record on NIH RePORTER →